US WorldMeds® announced that the U.S. Food and Drug Administration has granted full approval to TECELRA® (afamitresgene autoleucel), with an expanded indication that now includes eligible patients as young as 12 years old. The therapy, which received its original accelerated approval in August 2024, remains the first and only FDA-approved engineered T-cell therapy for a […]
